Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Hugo Kohnke"'
Autor:
Pär Hallberg, Hans Smedje, Niclas Eriksson, Hugo Kohnke, Makrina Daniilidou, Inger Öhman, Qun-Ying Yue, Marco Cavalli, Claes Wadelius, Patrik K.E. Magnusson, Anne-Marie Landtblom, Mia Wadelius
Publikováno v:
EBioMedicine, Vol 40, Iss , Pp 595-604 (2019)
Background: The incidence of narcolepsy rose sharply after the swine influenza A (H1N1) vaccination campaign with Pandemrix. Narcolepsy is an immune-related disorder with excessive daytime sleepiness. The most frequent form is strongly associated wit
Externí odkaz:
https://doaj.org/article/920b24431bea4d3ea6c999f1e808a40e
Autor:
Marco, Cavalli, Niclas, Eriksson, Johanna Karlsson, Sundbaum, Matilda, Wallenberg, Hugo, Kohnke, Eva, Baecklund, Pär, Hallberg, Mia, Wadelius
Publikováno v:
Pharmacogenomics. 23(15)
Autor:
Johanna Karlsson, Sundbaum, Eva, Baecklund, Niclas, Eriksson, Hugo, Kohnke, Matilda, Wallenberg, Marco, Cavalli, Claes, Wadelius, Mia, Wadelius, Pär, Hallberg
Publikováno v:
Pharmacogenomics. 22(15)
Publikováno v:
Lakartidningen. 118
5-fluorouracil (5-FU) is still a cornerstone in drug treatment for cancer. Some patients starting standard dosed 5-FU will experience severe adverse events (SAEs). One mechanism behind SAEs is impaired dihydropyrimidine dehydrogenase (DPD) activity,
Autor:
Mia Wadelius, Julian B. S. Leathart, Andrea L. Jorgensen, Girvan Burnside, Hugo Kohnke, Peter Avery, Munir Pirmohamed, J. Eunice Zhang, Cheng Hock Toh, Ann K. Daly, Niclas Eriksson, Patrick Kesteven, Farhad Kamali, Christina Stafberg, Paula R Williamson, Christina Christersson, Bengt Wahlström, Toby Nicholson, Anke H. Maitland-van der Zee, Abstr Act
Publikováno v:
New England Journal of Medicine; Vol 369
Background The level of anticoagulation in response to a fixed-dose regimen of warfarin is difficult to predict during the initiation of therapy. We prospectively compared the effect of genotype-guided dosing with that of standard dosing on anticoagu
Autor:
Julian B. S. Leathart, Anke-Hilse Maitland-van der Zee, Talitha I. Verhoef, Mia Wadelius, Hugo Kohnke, Elaina Krishan, Rebecca Howard, Rita Barallon, Ann K. Daly, Rianne M F van Schie, David John French
Publikováno v:
Clinica Chimica Acta
Clinica Chimica Acta; Vol 412
Clinica Chimica Acta; Vol 412
Coumarin anticoagulants such as warfarin are used to treat and prevent thromboembolic events in patients. The required dosage is difficult to predict and the risk of over or under anticoagulation are dependent on several environmental and clinical fa
Autor:
Ryuya Horiuchi, Alexander Lezhava, Yasushi Kogo, Yukiyoshi Fujita, Mia Wadelius, Koujirou Yamamoto, Lena Ekström, Kyoko Obayashi, Atsuko Oguchi-Katayama, Paul E. Cizdziel, Cristine Skogastierna, Masahiko Kurabayashi, Hugo Kohnke, Tohru Aomori, Katsunori Nakamura, Yoshihide Hayashizaki, Yasumasa Mitani, Yuki Kawai, Takefumi Ishidao, Anders Rane, Masami Murakami
Publikováno v:
Clinical Chemistry. 55:804-812
Background: Polymorphisms of the CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) gene (CYP2C9*2, CYP2C9*3) and the VKORC1 (vitamin K epoxide reductase complex, subunit 1) gene (−1639G>A) greatly impact the maintenance dose for the dr
Publikováno v:
European Journal of Clinical Pharmacology. 61:381-388
Warfarin is an anticoagulant which acts through interference with the recycling of vitamin K in the liver, leading to reduced activation of several clotting factors. Apolipoprotein E plays a central role in the uptake of the lipid-soluble vitamin K.
Autor:
Bengt Glimelius, Hans Garmo, Mia Wadelius, Per Byström, Mattias Berglund, Hugo Kohnke, Åke Berglund, Halfdan Sorbye, L. A. Fredriksson
Publikováno v:
The Pharmacogenomics Journal
Irinotecan and 5-fluorouracil (5-FU) are used to treat metastatic colorectal cancer. Irinotecan's active metabolite is inactivated by UDP-glucuronosyltransferase 1A1 (UGT1A1), which is deficient in Gilbert's syndrome. Irinotecan and metabolites are t
Publikováno v:
European journal of clinical pharmacology. 61(10)
Sirs, Despite large interindividual differences in dose requirement and a narrow therapeutic range, warfarin is still the most widely prescribed anticoagulant for thromboembolic therapy. However, the problems with dose titration, especially during th